<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Potential New Standard for High-Risk, Pediatric B-Cell Lymphoma

Written by MedPage Today on June 5, 2020

“These outstanding results support rituximab as a new standard-of-care therapy for young patients with advanced B-cell non-Hodgkin lymphoma,” co-author Thomas Gross, of University of Colorado Cancer Center and Children’s Hospital Colorado, said.

Topics: Press Coverage

Comments